|
pubmed:abstractText |
1 A double-blind group comparative trial was performed comparing mianserin (Bolvidon-Organon) and doxepin (Sinequan-Pfizer) in the treatment of depression with anxiety. 2 Sixty outpatients from two centres were divided into 'high' and 'low' severity groups, based on initial HRS scores, and treated for four weeks. 3 Standard rating scales for depression and anxiety demonstrated a substantial improvement with both drugs. However, no consistent difference in efficacy was found although the 'low severity' group appeared to respond better to mianserin. 4 There was a greater incidence of drug-related side-effects with doxepin treatment.
|
